Registered Malawi · PMRA

LAMIVUDINE-NEVIRAPINE-ZIDOVUDINE 30MG/50MG/60MG DISPERSIBLE TABLET

LAMIVUDINE-NEVIRAPINE-ZIDOVUDINE

PMPB/PL354/26 DISPERSIBLE TABLET antiinfectives for systemic use

What it does

This medicine combines three active ingredients to help manage HIV infections.

Commonly used for: HIV infection (human immunodeficiency virus), AIDS (acquired immunodeficiency syndrome)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
PMPB/PL354/26
Registration date
27/04/2012
Expiry date
30/06/2019
Status
Registered
Active ingredient
LAMIVUDINE-NEVIRAPINE-ZIDOVUDINE
Dosage form
DISPERSIBLE TABLET
Strength
-
Pack size
-
Therapeutic class
-
ATC class (WHO)
J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors
Drug group
ANTIINFECTIVES FOR SYSTEMIC USE
RxNorm RxCUI
687428
Manufacturer / MAH
-
Applicant / LTR
-
Country of origin
-

Source: Pharmacy and Medicines Regulatory Authority · fetched 2026-04-21 17:37:41 · updated 2026-09-29 04:33:05

Disclaimer: This information is sourced from Pharmacy and Medicines Regulatory Authority (Malawi). Always consult a qualified healthcare professional before using any medication.

About this medicine

This medicine combines three active ingredients to help manage HIV infections.

What it treats

  • HIV infection (human immunodeficiency virus)
  • AIDS (acquired immunodeficiency syndrome)

How it works

It works by stopping the virus from multiplying in the body, helping to improve immune function.

Who it's for

This medication is for people diagnosed with HIV to help control the virus.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: lamivudinenevirapinezidovudine

Lamivudine, Nevirapine, and Zidovudine are antiretroviral medications used in the treatment of Human Immunodeficiency Virus (HIV) infection. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits viral replication. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to the reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA. Zidovudine, also an NRTI, interferes with the viral replication process by incorporating itself into the viral DNA. This combination therapy aids in improving immune function and reducing viral load in HIV-infected patients.

Indications

  • HIV infection
  • AIDS-related conditions
  • Prevention of HIV transmission from mother to child

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations.

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

Lamivudine and Zidovudine act as nucleoside analogs, which are incorporated into the viral DNA by reverse transcriptase, leading to chain termination. Nevirapine binds to and inhibits the reverse transcriptase enzyme, preventing the transcription of viral RNA into DNA. This multi-modal approach effectively halts HIV replication and reduces viral load.

Pharmacodynamics

The pharmacodynamics of this combination therapy is characterized by its ability to inhibit viral replication, thereby reducing the viral load in the bloodstream. This leads to an increase in CD4 cell counts, improving immune function. The synergistic effects of combining NRTIs with NNRTIs enhance the overall efficacy of treatment and reduce the likelihood of developing drug resistance.

Pharmacokinetics

Lamivudine is rapidly absorbed and has a bioavailability of approximately 86%. It is primarily eliminated through renal excretion. Zidovudine is also well absorbed with a bioavailability of about 60-70%, and it is metabolized in the liver. Nevirapine exhibits good oral bioavailability and is extensively metabolized by the liver, leading to significant drug interactions with other medications. The half-lives of these drugs vary, necessitating careful consideration when dosing in combination therapy.

Adverse effects

  • Nausea
  • Diarrhea
  • Fatigue
  • Headache
  • Insomnia
  • Rash
  • Liver toxicity
  • Bone marrow suppression

Interactions

  • Use with other antiretroviral drugs may increase the risk of adverse effects
  • Caution with drugs that affect liver enzymes
  • Potential interactions with drugs metabolized by CYP450 system

Precautions

  • Monitor liver function tests regularly
  • Assess for signs of hypersensitivity reactions
  • Use cautiously in patients with renal impairment
  • Consider potential for drug resistance

Pregnancy

Use with caution. Limited data suggests potential risks, but benefits may outweigh risks in specific cases.

Breast-feeding

Limited data available; however, the drug is excreted in breast milk. Weigh the benefits of breastfeeding against potential risks.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

  • Tablets
  • Oral solution
PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.